Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)

Weill Cornell Medicine (WCM)

Status: Completed

Conditions: Diffuse Large B-cell Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT00754117

0801009588

Details and patient eligibility

About

Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1). Patients will then undergo 2 cycles of chemotherapy with R/CHOP. 14 to 21 days following cycle 2 of R/CHOP, patients will undergo repeat FDG-PET scan (PET-2). They will then complete therapy as planned. Following completion of therapy, standard response assessment will be performed, including CT scans of the chest, abdomen and pelvis and FDG-PET scan (PET-3).

Enrollment: 8 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must have histologically or cytologically confirmed diagnosis of CD20+ diffuse large B cell lymphoma (LBCL) of any stage, including subtypes mediastinal large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic B cell lymphoma
• Patients must have received no prior anti-lymphoma therapy.
• Age >18 years.
• Patients must have a treatment plan to include R/CHOP or R/CHOP followed by radiotherapy.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

• Patients who have known HIV infection.
• Patients who are, in the opinion of their treating oncologist, unable to undergo R/CHOP chemotherapy.

Trial design

8 participants in 1 patient group

All patients

Description:

All patients